<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00127777</url>
  </required_header>
  <id_info>
    <org_study_id>ML17002</org_study_id>
    <nct_id>NCT00127777</nct_id>
  </id_info>
  <brief_title>Peginterferon Alfa-2a, Ribavirin, Amantadine/Placebo in Hepatitis C Virus (HCV)-Genotype-1-Infection (PRAMA)</brief_title>
  <official_title>Randomized, Multi-Center, Partially Placebo-Controlled Phase IV-Study to Compare Efficacy and Tolerability of 48-Week Combined Therapy With Peginterferon Alfa-2a, Ribavirin and Amantadine Sulphate Versus Placebo in Untreated Patients With Chronic Hepatitis C Virus-Genotype-1-Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Saarland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Saarland</source>
  <brief_summary>
    <textblock>
      This was a randomized, multi-center, partially placebo-controlled Phase IV study to compare&#xD;
      the efficacy and tolerability of a 48-week combined therapy with pegylated interferon&#xD;
      alpha-2a, ribavirin and amantadine sulphate versus placebo in untreated patients with chronic&#xD;
      hepatitis C virus-genotype-1-infection. The hypothesis was that there will be an increase in&#xD;
      sustained response rate for triple therapy compared to current standard treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:&#xD;
&#xD;
        -  Proof that a triple-therapy (peginterferon alfa-2a, ribavirin and amantadine sulphate)&#xD;
           dispensed over a period of 50 weeks, improves the permanent virological efficacy by more&#xD;
           than 10% as compared to a combination therapy with peginterferon alpha-2a and ribavirin,&#xD;
           defined as negative HCV-RNA result obtained by a molecular verification method (e.g.&#xD;
           Roche AmplicorTM HCV, v.2.0, sensitivity &lt;50 IE/ml) 24 weeks after the end of the&#xD;
           therapy.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  Verification of the initial virological efficacy up to week 12, defined as negative&#xD;
           HCV-RNA test results by means of quantitative proof methods, e.g. Roche AmplicorTM HCV&#xD;
           Monitor v.2.0 (sensitivity &lt;600 IE/ml).&#xD;
&#xD;
        -  Biochemical efficacy, defined by the serum GPT values 24 weeks after the end of the&#xD;
           therapy.&#xD;
&#xD;
        -  Virological efficacy, measured on the basis of the HCV-RNA values at the end of the&#xD;
           therapy.&#xD;
&#xD;
        -  Biochemical efficacy defined by the serum GPT values at the end of the therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2002</start_date>
  <completion_date>December 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proof that peginterferon alfa-2a, ribavirin and amantadine sulphate over a period of 50 weeks improves the permanent virological efficacy by more than 10% compared to peginterferon alfa-2a and ribavirin</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Verification of the initial virological efficacy up to week 12, defined as negative HCV-RNA test results by means of quantitative proof methods, e.g. Roche AmplicorTM HCV Monitor v.2.0 (sensitivity &lt;600 IE/ml)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical efficacy, defined by the serum GPT values 24 weeks after the end of the therapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Virological efficacy, measured on the basis of the HCV-RNA values at the end of the therapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical efficacy defined by the serum GPT values at the end of the therapy</measure>
  </secondary_outcome>
  <enrollment>700</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amantadine sulphate (in addition to standard treatment)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female and male subjects over 18 years of age and below 70 years of age&#xD;
&#xD;
          -  Serological indication of chronic hepatitis C infection with positive anti-HCV test&#xD;
             and serum HCV-RNA quantification &gt;600 IE/ml by means of quantitative proof methods,&#xD;
             e.g. Roche AmplicorTM HCV Monitor test, v.2.0.&#xD;
&#xD;
          -  Untreated patients with HCV-induced chronic infection.&#xD;
&#xD;
          -  Indication of a genotype HCV-1 on the basis of the reverse hybridizing assay Inno LiPA&#xD;
             from Bayer Versant (Innogenetics).&#xD;
&#xD;
          -  Increased GPT serum level on at least one determination date within the 56-day&#xD;
             screening phase prior to start of administration of study medication.&#xD;
&#xD;
          -  Histological identification of inflammatory activity in the liver, with or without an&#xD;
             indication of compensated cirrhosis, during the 24 months prior to start of the study.&#xD;
&#xD;
          -  Compensated liver disease (Child-Pugh Grade A).&#xD;
&#xD;
          -  Negative urine or serum pregnancy test in fertile female subjects within 24 hours&#xD;
             before taking the first dose of study medication.&#xD;
&#xD;
          -  During the administration of study medication and for 24 weeks after the treatment has&#xD;
             stopped, patients must apply two approved contraception methods, one of which must&#xD;
             have a barrier effect on the male, e.g. condom.&#xD;
&#xD;
        If one or more of the above inclusion criteria are not fulfilled, the patient is excluded&#xD;
        from the study!&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any known sensitive reaction to interferon, ribavirin or amantadine sulphate.&#xD;
&#xD;
          -  Pregnant or breast-feeding women and fertile women who do not practice contraception.&#xD;
&#xD;
          -  Male partners of pregnant women.&#xD;
&#xD;
          -  Previous treatment with interferon and/or ribavirin.&#xD;
&#xD;
          -  Treatment with systemic anti-neoplastic or immunomodulatory medication&#xD;
             (supraphysiologic doses of steroids or radiation included) within the last 6 months&#xD;
             prior to the study and throughout the whole study.&#xD;
&#xD;
          -  Immunosuppressed/immunocompromised patients.&#xD;
&#xD;
          -  Participation in a clinical study within the last three months.&#xD;
&#xD;
          -  Infection with HCV genotype-2, -3, -4, -5 or -6.&#xD;
&#xD;
          -  Positive indication of HBsAg, HIV antibodies in the screening phase.&#xD;
&#xD;
          -  Non-hepatitis C virus-induced chronic hepatitis (e.g. hematochromatosis, autoimmune&#xD;
             hepatitis, metabolic or alcoholic liver disease).&#xD;
&#xD;
          -  Decompensated liver cirrhosis or liver disease; Child-Pugh Grade B or C; or threshold&#xD;
             compensated liver disease.&#xD;
&#xD;
          -  Signs of a hepatocellular carcinoma within 2 months before the randomization, coupled&#xD;
             with existing or developing cirrhosis.&#xD;
&#xD;
          -  History of oesophagus varices haemorrhage.&#xD;
&#xD;
          -  Hemoglobin &lt;12 g/dl in female subjects and &lt;13 g/dl in male subjects in the screening&#xD;
             phase.&#xD;
&#xD;
          -  Subjects with a higher risk of anemia (e.g. thalassemia, spherocytosis, history of&#xD;
             gastrointestinal bleeding) or subjects for whom anemia could be a highly potential&#xD;
             medical risk.&#xD;
&#xD;
          -  Neutropenia &lt;1500 /µl or thrombocytopenia &lt;90,000 /µl diagnosed in the screening&#xD;
             phase.&#xD;
&#xD;
          -  Serum creatinine &gt;1.5 mg/dl in the screening phase.&#xD;
&#xD;
          -  History of severe psychiatric diseases, especially severe depression, whereby severe&#xD;
             psychiatric disease is defined as any anti-depressive or anti-psychotic therapy of at&#xD;
             least 3 months in the history, or any indication of suicidal inclination or&#xD;
             hospitalization caused by a psychiatric disease.&#xD;
&#xD;
          -  Epilepsy.&#xD;
&#xD;
          -  Autoimmune disease (e.g. inflammatory intestinal diseases, idiopathic thrombocytopenic&#xD;
             purpura, lupus erythematosus sclerodermia, severe psoriasis, rheumatoid arthritis,&#xD;
             etc.).&#xD;
&#xD;
          -  History of thyroid disease, poorly controlled by prescribed medications&#xD;
&#xD;
          -  Chronic pulmonary disease with functional restriction.&#xD;
&#xD;
          -  History of severe cardiac disease, e.g. cardiac insufficiency New York Heart&#xD;
             Association (NYHA) class III or IV; myocardial infarction within the last 6 months;&#xD;
             ventricular tachyarrhythmia requiring treatment; unstable angina pectoris;&#xD;
             cerebrovascular circulation disorders; or other significant cardiovascular diseases.&#xD;
&#xD;
          -  Patients with pacemakers.&#xD;
&#xD;
          -  Cardiomyopathy and myocarditis&#xD;
&#xD;
          -  Atrioventricular (AV)-block Grade II and III.&#xD;
&#xD;
          -  Previously known bradycardia rating under 55 strokes/minute&#xD;
&#xD;
          -  Known, lengthy QT-interval (QTc as per Bazett &gt; 420 ms) or recognizable U waves or&#xD;
             hereditary QT-syndrome in the family history.&#xD;
&#xD;
          -  History of a severe ventricular arrythmia including Torsade de pointes.&#xD;
&#xD;
          -  Simultaneous therapy with budipine or other QT-extending medication such as:&#xD;
&#xD;
               -  Certain antiarrhythmias of class IA (e.g. quinidine, disopyramide, procainamide)&#xD;
                  and class III (such as amiodarone, sotalol);&#xD;
&#xD;
               -  Certain antipsychotics (e.g. thioridazine, chlorpromazine, haloperidol,&#xD;
                  pimozide);&#xD;
&#xD;
               -  Certain tri- and tetracyclic anti-depressive medications (e.g. amitriptyline);&#xD;
&#xD;
               -  Certain antihistaminic medications (e.g. astemizol, terfenadin);&#xD;
&#xD;
               -  Certain macrolide antibiotics (e.g. erythromycin, clarithromycin);&#xD;
&#xD;
               -  Certain gyrase inhibitors (e.g. sparfloxacin);&#xD;
&#xD;
               -  Azole-antimycotics and other medications such as halofantrine, cotrimoxazol,&#xD;
                  pentamidine, cisapride or bepridil;&#xD;
&#xD;
               -  Simultaneous treatment with Memantine.&#xD;
&#xD;
          -  Morbus Parkinson.&#xD;
&#xD;
          -  History of major organ transplantations, with the exception of cornea transplantation.&#xD;
&#xD;
          -  Cancer or any other disease, which, in the opinion of the investigator, is an&#xD;
             exclusion criterion for the study.&#xD;
&#xD;
          -  Evidence of severe retinopathy (e.g. cytomegalovirus [CMV] retinitis or macular&#xD;
             degeneration).&#xD;
&#xD;
          -  Patients with narrow-angle glaucoma.&#xD;
&#xD;
          -  Active drug abuse (excessive alcohol consumption included) within the last year prior&#xD;
             to study (with the exception of a prescribed substitute).&#xD;
&#xD;
          -  Patients with state of agitation or confusion&#xD;
&#xD;
          -  Patients with a history of acute brain syndrome or exogenous psychosis&#xD;
&#xD;
          -  Patients are already enrolled in the study.&#xD;
&#xD;
          -  Prostate hypertrophy&#xD;
&#xD;
          -  Simultaneous administering of diuretics of combination type&#xD;
             triamterene/hydrochlorothiazide.&#xD;
&#xD;
          -  Unwillingness or incapability to give written consent after receiving medical&#xD;
             information; doubts about the proper protection of patient data; and general&#xD;
             reluctance to take part in the study and to adhere to the study terms.&#xD;
&#xD;
        If one or more of these exclusion criteria is fulfilled, the patient shall be excluded from&#xD;
        the study!&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Zeuzem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saarland University Hospital</affiliation>
  </overall_official>
  <verification_date>August 2005</verification_date>
  <study_first_submitted>August 4, 2005</study_first_submitted>
  <study_first_submitted_qc>August 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2005</study_first_posted>
  <last_update_submitted>August 24, 2005</last_update_submitted>
  <last_update_submitted_qc>August 24, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2005</last_update_posted>
  <keyword>HCV genotype 1</keyword>
  <keyword>peginterferon alfa-2a</keyword>
  <keyword>ribavirin</keyword>
  <keyword>amantadine</keyword>
  <keyword>treatment-naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amantadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

